Recall Details
The U.S. Food and Drug Administration (FDA) published a notice on August 24, 2026, announcing that Vitruvias Therapeutics Inc. is recalling one lot of its 30mg Thyroid Tablets, USP nationwide. The affected products have an expiration date of September 30, 2026, and were distributed nationwide between January and September 2025.
Reason for Recall: Superpotency
Testing confirmed that the product could be superpotent, meaning stronger than intended. Consuming superpotent thyroid medication may lead to hyperthyroidism (overactive thyroid), causing symptoms such as weight loss, heat intolerance, fatigue, and hypertension.
Identifying Affected Products
- Product Name: Thyroid Tablets, USP
- Strength: 30mg
- NDC Number: 69680-166-00
- Lot Number: 504950
- Expiration Date: September 30, 2026
- Distribution Period: January 31 – September 30, 2025
Of the 3,600 units released, approximately 1,900 were sold from the batch. No adverse events related to this recall have been reported to the company so far.
Patient Guidance
Patients currently taking the recalled tablets should not stop taking them without first contacting their healthcare provider for further guidance. For questions, consumers can contact Vitruvias Therapeutics at:
- Email: safety@vitruvias.com
- Phone: 256-239-9373
Thyroid medication management requires professional monitoring. Patients are encouraged to use the Xiaoshu Health App to sync thyroid-related metrics (such as TSH, T3, T4) from Apple Health, enabling better communication with their healthcare providers about any changes in their condition.